<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04630925</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-188-20, B</org_study_id>
    <nct_id>NCT04630925</nct_id>
  </id_info>
  <brief_title>In-hospital Diabetes Management With Flash Glucose Monitoring (isCGM) - the INDIGO Study, Part B</brief_title>
  <acronym>INDIGO</acronym>
  <official_title>In-hospital Diabetes Management With Flash Glucose Monitoring (isCGM) - the INDIGO Study, Part B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the applicability of a Flash glucose monitoring sensor&#xD;
      (Freestyle Libre, isCGM) for in-hospital glucose monitoring in patients with diabetes and&#xD;
      hypoglycemia (&lt;3,9 mmol/l) during the hospitalization&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients who meet study criteria will be invited to participate in the study. All&#xD;
      patients included in the study will be followed by a trained clinical diabetes specialist and&#xD;
      a trained study nurse (study personnel) for glucose management during their hospitalization.&#xD;
      All patients included in the study will receive a Freestyle Libre isCGM. The patients will be&#xD;
      randomized to control (blinded isCGM glucose values to patient and study personnel and POC&#xD;
      (point-of-care) plasma glucose will be used for adjusting diabetes treatment) or intervention&#xD;
      (isCGM blood glucose values will be used to aid with glucose management during the&#xD;
      hospitalization). The study personnel will work with the patient's care team.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose time in range (3,9-10 mmol/l) (% pr day)</measure>
    <time_frame>2-14 days</time_frame>
    <description>Glucose time in range (3,9-10 mmol/l) when diabetes treatment is adjusted using isCGM compared with standard care using POC plasma glucose monitoring (PG) (% pr day)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean glucose (mmol/l) isCGM versus POC PG</measure>
    <time_frame>2-14 days</time_frame>
    <description>Mean glucose (mmol/l) when diabetes treatment is adjusted using isCGM compared with standard care using POC plasma glucose monitoring (PG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic variability; coefficient of variation (CV) and standard deviation (SD)</measure>
    <time_frame>2-14 days</time_frame>
    <description>CV and SD when diabetes treatment is adjusted using isCGM compared with standard care using POC plasma glucose monitoring (PG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and duration of events with hypoglycemia (&lt;3 mmol/L and &lt;3,9 mmol/l) (time in hypoglycemia)</measure>
    <time_frame>2-14 days</time_frame>
    <description>Number and duration of events with hypoglycemia when diabetes treatment is adjusted using isCGM compared with standard care using POC plasma glucose monitoring (PG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in hyperglycemia (&gt;10 mmol/l)</measure>
    <time_frame>2-14 days</time_frame>
    <description>Time in hyperglycemia when diabetes treatment is adjusted using isCGM compared with standard care using POC plasma glucose monitoring (PG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose out of range: Time in hypoglycemia and time in hyperglycemia (&lt;3,9 and &gt;10 mmol/l) undetected with POC PG (use of data from blinded CGM in control group)</measure>
    <time_frame>2-14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily total insulin dosage (IE)</measure>
    <time_frame>2-14 days</time_frame>
    <description>Daily total insulin dosage (IE) when diabetes treatment is adjusted using isCGM compared with standard care using POC plasma glucose monitoring (PG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time with active isCGM</measure>
    <time_frame>2-14 days</time_frame>
    <description>Time with active isCGM (%) in intervention group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>isCGM-arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CGM data will be viewed real-time and used to adjust diabetes treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>POC-arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>POC glucose readings are used to adjust diabetes treatment. CGM data are blinded to all and only gathered for comparison purposes to intervention group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>isCGM</intervention_name>
    <description>As previously described</description>
    <arm_group_label>isCGM-arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Expected length of hospital stay of at least 48 hours&#xD;
&#xD;
          -  Diagnosed with diabetes&#xD;
&#xD;
          -  Literate in Danish&#xD;
&#xD;
          -  In-hospital hypoglycemia with at least one POC glucose &lt; 3,9 mmol/l (current&#xD;
             hospitalization)&#xD;
&#xD;
          -  In-hospital treatment with insulin or sulfonylurea&#xD;
&#xD;
          -  Admission to Department of Gastrointestinal Surgery or Department of Heart-, Lung-,&#xD;
             and Vascular surgery, both at Aarhus University Hospital, Denmark.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patient unable to provide informed consent&#xD;
&#xD;
          -  Patient unable to use mobile phone for reading isCGM sensor&#xD;
&#xD;
          -  Known allergy to adhesives&#xD;
&#xD;
          -  Anticipated MRI during the hospital admission&#xD;
&#xD;
          -  Patients using CGM prior to hospital admission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Støy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie Støy, MD</last_name>
    <phone>+4522956817</phone>
    <email>julistoe@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Esben Søndergaard, MD</last_name>
    <phone>+4528730943</phone>
    <email>esbensoe@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus university hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Støy, MD PHD</last_name>
      <phone>+4522956817</phone>
      <email>julistoe@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Esben Søndergaard, MD PHD</last_name>
      <phone>+4528730943</phone>
      <email>esbensoe@rm.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>November 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Julie Støy</investigator_full_name>
    <investigator_title>Clinical diabetes specialist</investigator_title>
  </responsible_party>
  <keyword>Hypoglycemia</keyword>
  <keyword>Continuous glucose monitoring</keyword>
  <keyword>Hospitalization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

